BOSTON, July 29, 2016 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Monday, August 1, 2016 at 8:30 a.m. ET to discuss its second quarter 2016 financial results and provide a company update.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 58777481. The call will be webcast live and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Senior Director, Investor Relations
Keryx Biopharmaceuticals, Inc.